BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells  TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 30, 2020
Deals

F-Star lands on NASDAQ sooner than expected via reverse merger

At the year’s start F-Star Therapeutics’ plan was to ride out the expected volatility of the U.S. election year and seek a public listing in 2021. That changed when Spring Bank called with an opportunity...
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection  Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout  Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb  In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
Items per page:
1 - 10 of 1342